SubsidieMeestersTargeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological Malignancies
This project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility.
Projectdetails
Introduction
5-hydroxymethylcytosine (5hmC) is an oxidized form of 5-methylcytosine (5mC). It is the first step of reversing DNA methylation and an important indicator of dynamic epigenetic changes in genomic DNA.
Importance in Cancer
One characteristic of cancerous transformations is the dramatic modulation of the epigenomic landscape. Consequently, changes in the distribution of 5hmC have been shown to correlate with a broad range of cancers and are potentially a powerful disease biomarker.
Challenges in Current Methods
Nevertheless, existing methods for mapping 5hmC are complex and expensive, thus hindering the translation of 5hmC research into clinical use.
Project Objectives
This project aims at developing a custom DNA chip for 5hmC that will allow cost-effective and targeted analysis of disease biomarkers.
Methodology
- We will use our patented procedure for direct fluorescent labeling of 5hmC.
- This will be combined with commercially available genome-wide microarrays to create maps of 5hmC distribution in health and disease.
- These large-scale arrays will be used in the discovery phase to identify cancer biomarkers.
Custom Microarray Development
In the second phase, only the subset of genomic loci that contain medically significant modulation in 5hmC will be used to design and print a custom microarray containing only the relevant probes.
Expected Outcomes
This concept predicts a cost reduction of 10-100 fold, which will remove the barriers for large-scale research and high-volume testing. Disease-specific diagnostic chips are attractive products with direct impact on society and the economy via promoting more accessible testing and patient management.
Preliminary Results
Our preliminary results indicate that we will be able to offer a universal platform for even the most challenging samples, including cell-free DNA analysis from liquid biopsies.
Vision for the Future
We envision it as an enabling technology for 5hmC research, biomarker discovery, and companion diagnostics for guiding and monitoring therapy.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 31-5-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TEL AVIV UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Decoding the Combinatorial Epigenetic Information of the Mammalian Genome with Engineered DNA Duplex ReadersDeveloping and commercializing user-friendly kits for mapping novel CpG duplex modifications to enhance epigenetics research and cancer biomarker discovery. | ERC Proof of... | € 150.000 | 2022 | Details |
Deep multiplexed epigenetic profiling of plasma cell-free nucleosomes for early cancer diagnosticsThis project aims to develop ultra-sensitive methods for detecting histone post-translational modifications in blood plasma to enhance cancer diagnostics and enable universal screening. | ERC Proof of... | € 150.000 | 2024 | Details |
Towards early cancer detection and tumor classification using epigenomic biomarkers in bloodEpiCblood aims to enhance early cancer detection by increasing cancer-specific cf-nucleosomes through innovative histone modification profiling and computational analysis for improved liquid biopsy assays. | ERC Starting... | € 1.499.999 | 2024 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and DiagnosisEpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors. | ERC Starting... | € 1.500.000 | 2024 | Details |
Decoding the Combinatorial Epigenetic Information of the Mammalian Genome with Engineered DNA Duplex Readers
Developing and commercializing user-friendly kits for mapping novel CpG duplex modifications to enhance epigenetics research and cancer biomarker discovery.
Deep multiplexed epigenetic profiling of plasma cell-free nucleosomes for early cancer diagnostics
This project aims to develop ultra-sensitive methods for detecting histone post-translational modifications in blood plasma to enhance cancer diagnostics and enable universal screening.
Towards early cancer detection and tumor classification using epigenomic biomarkers in blood
EpiCblood aims to enhance early cancer detection by increasing cancer-specific cf-nucleosomes through innovative histone modification profiling and computational analysis for improved liquid biopsy assays.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis
EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
Best-in-class canceR dIaGnostic cHip for patient sTratification.The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression. | EIC Accelerator | € 2.497.880 | 2022 | Details |
Chemometric histopathology via coherent Raman imaging for precision medicineThe CHARM project aims to revolutionize cancer diagnosis with a novel AI-integrated, label-free tissue analysis system, achieving high accuracy in tumor identification and classification. | EIC Transition | € 2.441.979 | 2022 | Details |
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
Best-in-class canceR dIaGnostic cHip for patient sTratification.
The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.
Chemometric histopathology via coherent Raman imaging for precision medicine
The CHARM project aims to revolutionize cancer diagnosis with a novel AI-integrated, label-free tissue analysis system, achieving high accuracy in tumor identification and classification.